Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
A phase 2 trial of Cinacalcet in Prostate cancer, run by Wake Forest University Health Sciences, completed.
Overview
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer is a phase 2 interventional study registered as NCT01054079 by Wake Forest University Health Sciences, with 20 participants recorded, started 2011-09 and reaching its primary completion in 2014-08. Interventions recorded: laboratory biomarker analysis, quality-of-life assessment, questionnaire administration, cinacalcet hydrochloride. Conditions recorded: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer.
Linked to the drug Cinacalcet because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialEvaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Shares Prostate cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Prostate cancer and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialFirst-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialStudy of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
Shares Prostate cancer and the tag pipeline.